PT - JOURNAL ARTICLE AU - Yang, Bingyi AU - Lin, Yun AU - Xiong, Weijia AU - Liu, Chang AU - Gao, Huizhi AU - Ho, Faith AU - Zhou, Jiayi AU - Zhang, Ru AU - Wong, Jessica Y. AU - Cheung, Justin K. AU - Lau, Eric H. Y. AU - Tsang, Tim K. AU - Xiao, Jingyi AU - Wong, Irene O. L. AU - Martín-Sánchez, Mario AU - Leung, Gabriel M. AU - Cowling, Benjamin J. AU - Wu, Peng TI - Comparison of control and transmission of COVID-19 across epidemic waves in Hong Kong: an observational study AID - 10.1101/2023.06.20.23291593 DP - 2023 Jan 01 TA - medRxiv PG - 2023.06.20.23291593 4099 - http://medrxiv.org/content/early/2023/06/20/2023.06.20.23291593.short 4100 - http://medrxiv.org/content/early/2023/06/20/2023.06.20.23291593.full AB - Background Hong Kong contained COVID-19 for two years, but experienced a large epidemic of Omicron BA.2 in early 2022 and endemic transmission of Omicron subvariants thereafter.Methods We examined the use and impact of pandemic controls in Hong Kong by analysing data on more than 1.7 million confirmed COVID-19 cases and characterizing non-pharmaceutical and pharmaceutical interventions implemented from January 2020 through to 30 December 2022. We estimated the daily effective reproductive number (Rt) to track changes in transmissibility and effectiveness of community-based measures against infection over time. We examined the temporal changes of pharmaceutical interventions, mortality rate and case-fatality risks (CFRs), particularly among older adults.Findings Hong Kong experienced four local epidemic waves predominated by the ancestral strain in 2020 and early 2021 and prevented multiple SARS-CoV-2 variants from spreading in the community before 2022. Strict travel-related, case-based, and community-based measures were increasingly tightened in Hong Kong over the first two years of the pandemic. However, even very stringent measures were unable to contain the spread of Omicron BA.2 in Hong Kong. Despite high overall vaccination uptake (>70% with at least two doses), high mortality was observed during the Omicron BA.2 wave due to lower vaccine coverage (42%) among adults ≥65 years of age. Increases in antiviral usage and vaccination uptake over time through 2022 was associated with decreased case fatality risks.Interpretation Integrated strict measures were able to reduce importation risks and interrupt local transmission to contain COVID-19 transmission and disease burden while awaiting vaccine development and rollout. Increasing coverage of pharmaceutical interventions among high-risk groups reduced infection-related mortality and mitigated the adverse health impact of the pandemic.Competing Interest StatementBJC consults for AstraZeneca, Fosun Pharma, GSK, Haleon, Moderna, Pfizer, Roche, and Sanofi Pasteur. The authors report no other potential conflicts of interest.Funding StatementThis project was supported by the Health and Medical Research Fund from the Health Bureau of the Hong Kong SAR Government (grant numbers COVID190118 and 21200212), and the Collaborative Research Scheme (Project No. C7123-20G), the Theme-based Research Scheme (Project No. T11-705/21-N) and the General Research Fund (Project No. 17110221) from the Research Grants Council of the Hong Kong SAR Government. The telephone surveys were supported by the Health and Medical Research Fund (ref: COVID19F04, COVID19F11) from the Health Bureau of the Hong Kong SAR Government. The funding bodies had no role in the design of the study or in the analysis and interpretation of data.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster of The University of Hong Kong gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors